No Data
Express News | Carisma Therapeutics Inc: Got Notice of Failure to Satisfy a Continued Listing Rule or Standard From Nasdaq
Buy Rating for Carisma Therapeutics Amid Expansion Into Autoimmune Treatments With Moderna Collaboration
Moderna, Carisma Deal Expands With Autoimmune Targets
Express News | Carisma Therapeutics Inc - Eligible for Milestones and Royalty Payments
Express News | Carisma Therapeutics Inc - to Handle Discovery, Moderna to Lead Clinical Development
Express News | Carisma and Moderna Expand Collaboration to Develop Two in Vivo Car-M Therapies for Autoimmune Diseases
No Data
No Data
